Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was downgraded by analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating in a research note issued to investors on Friday, MarketBeat Ratings reports. They presently have a $395.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $450.00. Barclays PLC’s target price suggests a potential downside of 8.77% from the company’s current price.

Several other research firms also recently weighed in on REGN. Leerink Swann reaffirmed a “positive” rating and issued a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Piper Jaffray Companies reissued an “overweight” rating and set a $557.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group LLC reissued a “hold” rating and set a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Finally, Robert W. Baird reissued a “sell” rating and set a $408.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, September 8th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $487.80.

Regeneron Pharmaceuticals (REGN) traded down 1.81% during mid-day trading on Friday, hitting $432.98. 990,334 shares of the company were exchanged. The company’s 50-day moving average is $451.08 and its 200 day moving average is $456.76. The company has a market capitalization of $45.91 billion, a P/E ratio of 43.44 and a beta of 1.62. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 earnings per share. Analysts expect that Regeneron Pharmaceuticals will post $14.94 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/21/regeneron-pharmaceuticals-inc-regn-downgraded-by-barclays-plc.html.

In other news, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,468 shares of company stock valued at $42,312,448. Corporate insiders own 10.80% of the company’s stock.

Several institutional investors have recently modified their holdings of REGN. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $130,000. Sterling Investment Advisors Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares in the last quarter. FNY Managed Accounts LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $140,000. FNY Partners Fund LP increased its stake in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares in the last quarter. Finally, Alpha Windward LLC increased its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares in the last quarter. Institutional investors own 67.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.